Modulating P1 Adenosine Receptors in Disease Progression of SOD1 G93A Mutant Mice

Monica Armida, Alessandra Matteucci, Antonella Pèzzola, Younis Baqi, Christa E. Müller, Patrizia Popoli, Rosa Luisa Potenza

Research output: Contribution to journalArticle

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused. The present study was designed to determine whether P1 adenosine receptor ligands affected disease progression in a transgenic model of ALS. SOD1 G93A mice were chronically treated, from presymptomatic stage, with a selective adenosine A 2A receptor agonist (CGS21680), antagonist (KW6002) or the A 1 receptor antagonist DPCPX. Body weight, motor performance and survival time were evaluated. The results showed that neither the stimulation nor the blockade of adenosine A 2A receptors modified the progressive loss of motor skills or survival of mSOD1 G93A mice. Conversely, blockade of adenosine A 1 receptors from the presymptomatic stage significantly attenuated motor disease progression and induced a non-significant increase of median survival in ALS mice. Our data confirm that the modulation of adenosine receptors can elicit very different (and even opposite) effects during the progression of ALS course, thus strengthens the importance of further studies to elucidated their real therapeutic potential in this pathology.

Original languageEnglish
JournalNeurochemical Research
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Purinergic P1 Receptors
Amyotrophic Lateral Sclerosis
Adenosine A2A Receptors
Disease Progression
Neurodegenerative diseases
Pathology
Adenosine
Modulation
Motor Skills
Ligands
Neurodegenerative Diseases
Therapeutics
Body Weight
Research

Keywords

  • Adenosine A receptors (A Rs)
  • Adenosine A receptors (A Rs)
  • Amyotrophic lateral sclerosis (ALS)
  • SOD1 mice

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Modulating P1 Adenosine Receptors in Disease Progression of SOD1 G93A Mutant Mice . / Armida, Monica; Matteucci, Alessandra; Pèzzola, Antonella; Baqi, Younis; Müller, Christa E.; Popoli, Patrizia; Potenza, Rosa Luisa.

In: Neurochemical Research, 01.01.2019.

Research output: Contribution to journalArticle

Armida, Monica ; Matteucci, Alessandra ; Pèzzola, Antonella ; Baqi, Younis ; Müller, Christa E. ; Popoli, Patrizia ; Potenza, Rosa Luisa. / Modulating P1 Adenosine Receptors in Disease Progression of SOD1 G93A Mutant Mice In: Neurochemical Research. 2019.
@article{9bd0ac28283e4f0780601dfdf159b832,
title = "Modulating P1 Adenosine Receptors in Disease Progression of SOD1 G93A Mutant Mice",
abstract = "Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused. The present study was designed to determine whether P1 adenosine receptor ligands affected disease progression in a transgenic model of ALS. SOD1 G93A mice were chronically treated, from presymptomatic stage, with a selective adenosine A 2A receptor agonist (CGS21680), antagonist (KW6002) or the A 1 receptor antagonist DPCPX. Body weight, motor performance and survival time were evaluated. The results showed that neither the stimulation nor the blockade of adenosine A 2A receptors modified the progressive loss of motor skills or survival of mSOD1 G93A mice. Conversely, blockade of adenosine A 1 receptors from the presymptomatic stage significantly attenuated motor disease progression and induced a non-significant increase of median survival in ALS mice. Our data confirm that the modulation of adenosine receptors can elicit very different (and even opposite) effects during the progression of ALS course, thus strengthens the importance of further studies to elucidated their real therapeutic potential in this pathology.",
keywords = "Adenosine A receptors (A Rs), Adenosine A receptors (A Rs), Amyotrophic lateral sclerosis (ALS), SOD1 mice",
author = "Monica Armida and Alessandra Matteucci and Antonella P{\`e}zzola and Younis Baqi and M{\"u}ller, {Christa E.} and Patrizia Popoli and Potenza, {Rosa Luisa}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11064-019-02745-0",
language = "English",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",

}

TY - JOUR

T1 - Modulating P1 Adenosine Receptors in Disease Progression of SOD1 G93A Mutant Mice

AU - Armida, Monica

AU - Matteucci, Alessandra

AU - Pèzzola, Antonella

AU - Baqi, Younis

AU - Müller, Christa E.

AU - Popoli, Patrizia

AU - Potenza, Rosa Luisa

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused. The present study was designed to determine whether P1 adenosine receptor ligands affected disease progression in a transgenic model of ALS. SOD1 G93A mice were chronically treated, from presymptomatic stage, with a selective adenosine A 2A receptor agonist (CGS21680), antagonist (KW6002) or the A 1 receptor antagonist DPCPX. Body weight, motor performance and survival time were evaluated. The results showed that neither the stimulation nor the blockade of adenosine A 2A receptors modified the progressive loss of motor skills or survival of mSOD1 G93A mice. Conversely, blockade of adenosine A 1 receptors from the presymptomatic stage significantly attenuated motor disease progression and induced a non-significant increase of median survival in ALS mice. Our data confirm that the modulation of adenosine receptors can elicit very different (and even opposite) effects during the progression of ALS course, thus strengthens the importance of further studies to elucidated their real therapeutic potential in this pathology.

AB - Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused. The present study was designed to determine whether P1 adenosine receptor ligands affected disease progression in a transgenic model of ALS. SOD1 G93A mice were chronically treated, from presymptomatic stage, with a selective adenosine A 2A receptor agonist (CGS21680), antagonist (KW6002) or the A 1 receptor antagonist DPCPX. Body weight, motor performance and survival time were evaluated. The results showed that neither the stimulation nor the blockade of adenosine A 2A receptors modified the progressive loss of motor skills or survival of mSOD1 G93A mice. Conversely, blockade of adenosine A 1 receptors from the presymptomatic stage significantly attenuated motor disease progression and induced a non-significant increase of median survival in ALS mice. Our data confirm that the modulation of adenosine receptors can elicit very different (and even opposite) effects during the progression of ALS course, thus strengthens the importance of further studies to elucidated their real therapeutic potential in this pathology.

KW - Adenosine A receptors (A Rs)

KW - Adenosine A receptors (A Rs)

KW - Amyotrophic lateral sclerosis (ALS)

KW - SOD1 mice

UR - http://www.scopus.com/inward/record.url?scp=85061488577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061488577&partnerID=8YFLogxK

U2 - 10.1007/s11064-019-02745-0

DO - 10.1007/s11064-019-02745-0

M3 - Article

AN - SCOPUS:85061488577

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

ER -